PET/Computed Tomography in Breast Cancer

Can It Aid in Developing a Personalized Treatment Design?

Sumeet Suresh Malapure, Kalpa Jyoti Das, Rakesh Kumar

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

PET with fluorodeoxyglucose (FDG-PET)/computed tomography (CT) imaging has significantly improved the management of breast cancer. FDG, however, is not tumor-specific and various image interpretation pitfalls may occur due to false-positive and false-negative causes of FDG uptake. PET/CT imaging with more specific radiopharmaceuticals may provide useful information about the pathophysiology in such cases. In the present article, we reviewed the use of whole-body FDG-PET/CT and 18F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.

Original languageEnglish
Pages (from-to)297-303
Number of pages7
JournalPET Clinics
Volume11
Issue number3
DOIs
Publication statusPublished - 01-07-2016
Externally publishedYes

Fingerprint

breast
tomography
cancer
Tomography
Breast Neoplasms
Radiopharmaceuticals
tumors
causes
Neoplasms

All Science Journal Classification (ASJC) codes

  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

Suresh Malapure, Sumeet ; Das, Kalpa Jyoti ; Kumar, Rakesh. / PET/Computed Tomography in Breast Cancer : Can It Aid in Developing a Personalized Treatment Design?. In: PET Clinics. 2016 ; Vol. 11, No. 3. pp. 297-303.
@article{d91346c3bc884a1da30dd7186b3e1f60,
title = "PET/Computed Tomography in Breast Cancer: Can It Aid in Developing a Personalized Treatment Design?",
abstract = "PET with fluorodeoxyglucose (FDG-PET)/computed tomography (CT) imaging has significantly improved the management of breast cancer. FDG, however, is not tumor-specific and various image interpretation pitfalls may occur due to false-positive and false-negative causes of FDG uptake. PET/CT imaging with more specific radiopharmaceuticals may provide useful information about the pathophysiology in such cases. In the present article, we reviewed the use of whole-body FDG-PET/CT and 18F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.",
author = "{Suresh Malapure}, Sumeet and Das, {Kalpa Jyoti} and Rakesh Kumar",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.cpet.2016.02.006",
language = "English",
volume = "11",
pages = "297--303",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",
number = "3",

}

PET/Computed Tomography in Breast Cancer : Can It Aid in Developing a Personalized Treatment Design? / Suresh Malapure, Sumeet; Das, Kalpa Jyoti; Kumar, Rakesh.

In: PET Clinics, Vol. 11, No. 3, 01.07.2016, p. 297-303.

Research output: Contribution to journalReview article

TY - JOUR

T1 - PET/Computed Tomography in Breast Cancer

T2 - Can It Aid in Developing a Personalized Treatment Design?

AU - Suresh Malapure, Sumeet

AU - Das, Kalpa Jyoti

AU - Kumar, Rakesh

PY - 2016/7/1

Y1 - 2016/7/1

N2 - PET with fluorodeoxyglucose (FDG-PET)/computed tomography (CT) imaging has significantly improved the management of breast cancer. FDG, however, is not tumor-specific and various image interpretation pitfalls may occur due to false-positive and false-negative causes of FDG uptake. PET/CT imaging with more specific radiopharmaceuticals may provide useful information about the pathophysiology in such cases. In the present article, we reviewed the use of whole-body FDG-PET/CT and 18F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.

AB - PET with fluorodeoxyglucose (FDG-PET)/computed tomography (CT) imaging has significantly improved the management of breast cancer. FDG, however, is not tumor-specific and various image interpretation pitfalls may occur due to false-positive and false-negative causes of FDG uptake. PET/CT imaging with more specific radiopharmaceuticals may provide useful information about the pathophysiology in such cases. In the present article, we reviewed the use of whole-body FDG-PET/CT and 18F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84963954460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963954460&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2016.02.006

DO - 10.1016/j.cpet.2016.02.006

M3 - Review article

VL - 11

SP - 297

EP - 303

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

IS - 3

ER -